This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Scopus Google Scholar Articles by Johnson, V. E Articles by Cook, J. D PubMed PubMed Citation Articles by Johnson, V. E Articles by Cook, J. D Social Bookmarking                         What's this?

Bayesian Design of Single-arm Phase II Clinical Trials with Continuous Monitoring

Department of Biostatistics, M.D. Anderson Cancer Center, Houston, TX, USA, vejohnson{at}mdanderson.org

John D Cook

Division of Quantitative Sciences, M.D. Anderson Cancer Center, Houston, TX, USA

Background Bayesian designs are increasingly used to conduct phase II clinical trials. However, stopping boundaries in most Bayesian designs are defined from posterior credible intervals. The use of designs based on posterior credible intervals results in a loss of efficiency when compared to formal stopping rules based on Bayesian hypothesis tests. Such designs also introduce an unnecessary element of subjectivity in the interpretation of trial results.

Methods We derive a new class of Bayesian designs based on formal hypothesis tests. The prior densities used to define the alternative hypotheses in these tests assign no mass to parameter values that are consistent with the null hypotheses and are called nonlocal alternative prior densities.

Results We show that Bayesian designs based on hypothesis tests and nonlocal alternative prior densities are more efficient than common Bayesian designs based on posterior credible intervals and common frequentist designs. In contrast to trial designs based on Bayesian credible intervals, we demonstrate that the mis-specification of the prior densities used to describe the anticipated effect of the experimental treatment in designs based on hypothesis tests cannot increase the expected weight of evidence in favor of the trial agent.

Limitations Extension of test-based designs to phase I—II designs and randomized phase II designs remains an open research question.

Conclusions Phase II single-arm trials designed using Bayesian hypothesis tests with nonlocal alternatives provide better operating characteristics, use fewer patients per correct decision, and provide more directly interpretable results than other commonly used Bayesian and frequentist designs. Because the mis-specification of the prior density on the effect of the experimental agent decreases the expected weight of evidence that is collected in favor of the experimental treatment, the use of Bayesian hypothesis tests to design clinical trials also eliminates a potential source of bias often associated with trials designed using posterior credible intervals.

Clinical Trials, Vol. 6, No. 3, 217-226 (2009)
DOI: 10.1177/1740774509105221


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Gonen Bayesian clinical trials: no more excuses Clinical Trials, June 1, 2009; 6(3): 203 - 204. [PDF]